LIVANOVA PLC DL -,01

LivaNova reported Q2 2026 adjusted EPS of $1.26 (expectation $1.09) and revenue of $390.6 million (expectation $380.57 million), up 10.8% year over year. Management raised the full-year guidance for adjusted diluted EPS to $4.30–4.40 (midpoint $4.35 vs. consensus $4.25). Growth drivers include the cardiopulmonary segment and the FDA-cleared aura6000 system for obstructive sleep apnea. KeyBanc reaffirmed its Overweight rating and raised its price target to $92, after which the stock hit a 52-week high and rose in after-hours trading. » More on de.investing.com

Shares of LivaNova rose to a 52-week high of $84.30 and are currently trading near that level, more than double their year low of $41.02. Over the past year the stock delivered a total return of 81%; an analysis by InvestingPro still rates the stock as undervalued relative to its fair value. Operationally, LivaNova reported promising SLEEP-2026 data for PolySync (response rate 84.5%) and announced several leadership changes, including Anne Liddy as chief legal officer and Stefano Folli as president cardiopulmonary; Freedom Capital assigned a hold rating with mid- to high-single-digit growth expectations. » More on de.investing.com

LivaNova elected Jette Nygaard-Andersen to its board at the annual general meeting on 10 June. Nygaard-Andersen is currently chair of Coloplast’s board and was previously CEO of Entain, as well as holding leadership roles at Modern Times Group. Her appointment coincides with the departure of Dr. Sharon O’Kane; Brooke Story will chair the nominations and corporate governance committee. Other board roles were reshuffled internally; LivaNova continues to employ about 3,300 people in more than 100 countries and the share is trading close to its 52-week high. » More on de.investing.com